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Gel chromatographic profile of dapsone (DDS) and anti-DDS
antibody in dissociated CIC for sera of two lepromatous pa-
tients.
G-200 column (1 x 10 cm); Vo=void volume and Vt=total volume of
column. Relative titre for anti-DDS (by ELISA6,’) and DDS concen-
tration (by ELISIT6’).
have no evidence that such complexes play any role in ENL.
Nevertheless, screening for antibody to dapsone and for CICs
of dapsone/anti-dapsone could be important in longitudinal
studies of the response of leprosy patients to chemotherapy.
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uria2 and Reye’s syndrome3 have been reported in epileptic
patients taking the anticonvulsant drug valproic acid (VPA).
While investigating possible mechanisms of VPA toxicity we
found increased plasma glycine and propionic acid concentra-
tions in symptom-free patients taking VPA (table i). With in-
formed consent, loading tests with 500 mg VPA orally were
done in three children who had experienced severe vomiting,
lethargy, or coma while on VPA. Plasma propionate rose from
baseline 5 to 82 nmol/1 (case 1), 21 to 81 nmol/1 (case 2), and
14 to 62 nmol/1 (case 3) by 3 h after the dose. However, these
data did not explain why some children became ill from VPA;
these levels of glycine and propionate are not nearly as high
7. Huikeshoven H, de Wit M, Soeters A, Eggelte TA, Landheer JE, Leiker DL.
Leprosy Rev (in press).
8. Ridley DS, Jopling WH. Classification of leprosy according to immunity: a
five group system. Int J Lepr 1966; 34: 255-73.
1. Jaeken J, Corbell L, Casaer P, Carchon H, Eggermont E, Eeckels R. Dipro-
pylacetate (valoproate) and glycine metabolism. Lancet, 1977, ii: 617.
2. Schmid RD: Propionic acic and dipropylacetic acid in the urine of patients
treated with dipropylacetic acid. Clin Chim Acta; 1977; 74: 39-42.
3. Gerber N, Dickinson RG, Harland RC, Lynn RK, Houghton D, Antonias
JI, Schimschock JC. Reye-like syndrome associated with valproic acid
therapy. J Pediat 1979; 95: 142-44.
TABLE I-GLYCINE AND PROPIONATE CONCENTRATIONS
*Normal range 1-3 nmol/l.
as those found in children ill with inborn errors of metabolism
involving these compounds.4,5
Recently, we observed hyperammonxmia in a patient taking
VPA who became obtunded but had no evidence of liver dis-
ease or drug intoxication. Since hyperammonaemia occurs in
several metabolic diseases, including propionyl CoA carboxy-
lase deficiency,6 we investigated a possible relation between
VPA, propionate, and ammonia that might suggest a mechan-
ism of VPA toxicity.
A 4-year-old 15 kg girl taking phenytoin 125 mg, primidone
175 mg, acetazolamide 375 mg, trimethadione 1800 mg, and
valproic acid 750 mg daily became lethargic with vomiting and
fever and progressive obtundation. Anticonvulsant levels, elec-
trolytes, liver and renal function tests, coagulation studies,
blood gases, cell counts, lactic acid, and CSF studies were nor-
mal. Ammonia was 80 mol/1 (control 28, normal 11-35) and
remained high for 4 days. VPA was discontinued on admission,
By day 5 she was alert, and ammonia was 36 umol/1 (control
30). With informed consent a 500 mg VPA load test was done
on day 7 (table II). Glycine was determined on a Beckman 119
TABLE II-VPA LOADING TEST RESULTS
*Hsemolysed.
CL amino-acid analyser, VPA and propionate were measured
by gas liquid chromatography, and ammonia by the glutamate
dehydrogenase method. 1 h after the loading dose, VPA, pro-
pionate, and ammonia levels had increased significantly and
the child became lethargic. As the levels returned to normal at
the end of the test, she again became alert.
Propionyl CoA inhibits carbamyl phosphate synthetase I
(CPS-1) activity in vitro’ so that blood ammonia may be in-
creased in patients with propionyl CoA carboxylase deficiency
with raised propionate levels.8 A decreased activity of CPS-1
has been reported in such patients.9 VPA apparently does not
inhibit propionyl CoA carboxylase activity,’O but metabolic
conversion of VPA to propionate and related compounds could
explain the increased propionate levels in patients taking VPA.
This increase in blood propionate may then inhibit CPS-1,
resulting in accumulation of ammonia in the blood and a
secondary ammonia encephalopathy. Since propionate may
4. Ando T, Rasmussen K, Nyhan WL, Donnel GN, Barnes ND. Propionic aci-
demia in patients with ketotic hyperglycinemia. J Pediat 1971; 78:
827-32.
5. Frazier DM, Summer GK, Chamberlin HR. Hyperglycinuria and hypergly-
cinemia in two siblings with mild developmental delays. Am J Dis Child
1978;132:777-81.
6. Shafai T, Sweetman L, Wegler W, Goodman SI, Fennessey PV, Nyhan WL.
Propionic acidemia with severe hyperammonemia and defective glycine
metabolism. J Pediat 1978; 92: 84-86.
7. Gruskay JA, Rosenberg LE. Inhibition of hepatic mitochondrial carbamyl
phosphate synthetase (CPS-I) by acyl CoA esters. Pediat Res 1979; 13:
475.
8. Wolf B, Hsia YE, Tanaka K, Rosenberg LE. Correlations between serum
propionate and blood ammonia concentrations in propionic acidemia. J
Pediat 1978; 93:471-73.
9. Harris DJ, Yang BIY, Wolf B, Snodgrass PJ. Dysautonomia in an infant
with secondary hyperammonemia due to propionyl CoA carboxylase
deficiency. Pediatrics 1980; 65:107-10.
10. Wolf B. Dipropylacetate and propionyl CoA carboxylase. Lancet;ii: 369.
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also interfere with mitochondrial glycine transport" this may
account for the hyperglycinamlia seen in patients taking VPA.
It has been suggested that N-acetyl glutamate synthetase is in-
hibited by increased propionyl CoA concentrations.6 Since
N-acetyl glutamate activates CPS-1, inhibited formation of this
compound could also reduce the activity of CPS-I.
It seems that secondary hyperammon2emia, not due to liver
disease, may occur in patients taking VPA, and this may
explain why some patients become stuporous or comatose
while taking this drug.12 Blood ammonia levels should be
monitored in such patients. The mechanism of ammonia ence-
phalopathy may be different from that of the hyperammonse-
mia seen in patients with hepatitis due to VPA. 1, 13
This child was on several drugs, and a single load test may
not compare with chronic use. Further studies of ammonia
metabolism in patients taking VPA should help clarify the
mechanism of VPA toxicity.
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THE IRISH GIANT: NEW OBSERVATIONS
CONCERNING THE NATURE OF HIS AILMENT
SiR,&mdash;Charles Byrne, the Irish giant who attracted consid-
erable interest when he came to London in 1782 and whose
skeleton is one of the main attractions of the Hunterian
Museum, continues to yield up new findings almost two
hundred years after his death in 1783 at the age of 22 years.
Sir Arthur Keith and Harvey Cushingl4-16 showed by direct
inspection of the pituitary fossa that Charles Byrne had a
pituitary adenoma causing the extraordinary growth of his
body. This was confirmed in 1963 by a skull radiograph which
demonstrated enlargement of the sella turcica.17 Some new in-
sights have now been provided by a reinspection of the skele-
ton, by a radiograph of its right hand kindly obtained by the
curator of the museum, Miss Elizabeth Allen, by some
measurements mentioned in the museum catalogue,18 and by
other measurements obtained from a photograph provided by
the Hunterian Museum.
On both wrists the distal epiphyseal lines of the radius are
open. This is not mentioned in the published description of the
skeleton, but is confirmed by the radiograph (see figure). John
Hunter must have noted this because he used additional nails
and wires to secure the radial epiphyses. Comparison with an
atlas of skeletal development’9 shows that Charles Byrne had
a bone maturity of only 17 years. Skeletal maturation there-
fore was retarded. Measurements of the skeleton are compared
with the normal values of a longitudinal growth study;20 the
11. Vgarte M, Lopez-Lahoya J, Garcia ML, Benavides J, Valdivieso F. Possible
explanation for hyperglycinemia in propionic acidemia and methylmalonic
acidemia. J Inher Metab Dis 1979;2:93-96.
12. Sackellaris JC, Lee SI, Dreifuss FE. Stupor following administration of val-
proic acid to patients receiving other anticonvulsant drugs. Epilepsia
1979;20:697-703.
13. Jacobi G, Thorbeck R, Ritz A, Jansen W, Schmidts HL. Fatal hepatotoxicity
in child on phenobarbitone and sodium valproate. Lancet 1980; i:
712-13.
14. Cushing H. Neurohypophysical mechanisms from a clinical standpoint. Lan-
cet 1930; ii: 119-27.
15. Fulton J. Harvey Cushing: a biography. Springfield, 7 Illinois: Charles C.
Thomas, 1946.
16. Keith A. An inquiry into the nature of the skeletal changes in acromegaly.
Lancet 1911; i: 993-1002.
17. Bergland RM. New information concerning the Irish Giant. J Neurosurg
1965;23:265-69.
18. Descriptive catalogue of the physiological series in the Hunterian Museum
of the Royal College of Surgeons of England, London, 1971.
19. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the
hand and wrist. Stanford: 1959.
20. Prader A, Issler C, Molinari L, Largo RH. Physical growth in Swiss children
from 0 to 20 years of life. Helv P&aelig;diat Acta 1980, suppl 45 (in press).
Radiograph of right wrist of Charels Byrne (O’Brien).
Arrows mark open epiphyseal cleft.
differences are expressed in standard deviation scores (SDS)
(see table).
A comparison of the dimension of the skeleton with today’s
normal growth values may not be valid because of secular ac-
celeration of growth over the past two centuries. However,
comparison with contemporary data would result in even
higher SDS values. The SDS value of the body height is
extreme and excludes the possibility that Charles Byrne was
just "a tall man". The relation of the height, sitting height,
and subischial leg height demonstrates that the giantism was
harmonic and not eunuchoidal. The measurements of the
head, shoulder width, and pelvic diameter give relatively lower
SD scores in comparison to the body height. This is the exact
opposite to the anthropometric signs produced by growth hor-
mone deficiency. 21
These data confirm that Charles Byrne had suffered from a
growth-hormone-producing adenoma. The tumour apparently
did not affect the gonadrotrophin production during early ado-
lescence since no eunuchoid proportions ensued. However,
21. Zachmann M, Fernandez F, Tassinari D, Thakker R, Prader A. Anthropo-
metric measurements in patients with growth hormone deficiency prior to
treatment with human growth hormone. Eur J J Pediat 1980; 133: 277-82.
ANTHROPOMETRIC MEASUREMENTS OBTAINED FROM THE
SKELETON OF CHARLES BYRNE IN COMPARISON TO THE NORMAL
VALUES OF A LONGITUDINAL GROWTH STUI’y7
*SDS= (x&mdash;x)&mdash;s;, where x= measurement, x= normal mean of young adult Swiss
males at age of 20 years, and s= standard deviation at that age.
